Lupin pulls over 9,000 bottles of anti-infective Suprax from US

Lupin Ltd is recalling 9,210 bottles of infection-preventing drug Suprax which failed a purity test in the United States, the US Food and Drug Administration said.

The Suprax recall is the second for India's fourth-largest drugmaker by sales, after pulling nearly 65,000 bottles from the U.S. in January last year because of discoloration.

Recalls are not uncommon among drugmakers. This year alone, recalls have been conducted by all of Lupin's bigger local rivals - Ranbaxy Laboratories Ltd, Sun Pharmaceutical Industries Ltd and Dr. Reddy's Laboratories Ltd.

The latest recalled bottles of Suprax, used to prevent or treat bacteria-related infection, "did not meet specification in total impurities", the FDA said on its website on Monday.

The FDA classified the incident as a Class III recall, meaning use of or exposure to the drug is unlikely to cause any adverse health consequences.

A Lupin spokesperson on Tuesday confirmed the recall, which began in January, and said the company expects "no business consequence".

The recent recalls come amid increased FDA scrutiny of medicines produced in India, which supplies about 40 percent of generic and over-the-counter drugs sold in the U.S.

Indian drugmakers are heavily reliant on the U.S. where Lupin, for instance, derives around 40 percent of sales.

In September, Lupin also recalled over 53,000 bottles of hypertension drug quinapril from the US.

Post new comment

E-mail ID will not be published
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

EDITORIAL OF THE DAY

  • Mutual fund stakeholders should focus on better returns in a bullish market

    The association of mutual fund of India (AMFI) has recently capped the commission paid to distributors of mutual fund schemes to a maximum of 1 per ce

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

Sarthak Raychaudhuri

vice-president, HR, Asia South Whirlpool of India

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

Today's Columns

Roopen Roy

What we can learn from Singapore

Lee Kuan Yew passed away at the age of 91 ...

Rajgopal Nidamboor

Don’t depend too much on ‘heroes’

We all have our own set of ‘heroes’ — not ...

Shona Adhikari

Anjolie Ela Menon, the storyteller, is back

Anjolie Ela Menon, one of India’s most celebrated artists, is ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture